We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

C4 Therapeutics Inc (CCCC) USD0.0001

Sell:$8.17 Buy:$8.20 Change: $0.02 (0.25%)
NASDAQ:0.12%
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$8.17
Buy:$8.20
Change: $0.02 (0.25%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$8.17
Buy:$8.20
Change: $0.02 (0.25%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how disease is treated. It leverages its technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to design and optimize small-molecule medicines that harness the body's natural protein recycling system to rapidly degrade disease-causing proteins. Its TORPEDO platform enables the discovery of targeted investigational small molecule medicines called protein degraders. Its advanced product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma (MM), and non-Hodgkin lymphomas (NHLs). Its other product candidate, CFT8634, is an orally bioavailable BiDAC degrader of a protein target called BRD9 for the treatment of synovial sarcoma and SMARCB1-null solid tumors.

Contact details

Address:
490 Arsenal Way, Suite 120
WATERTOWN
02472
United States
Telephone:
+1 (617) 2310700
Website:
https://c4therapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CCCC
ISIN:
US12529R1077
Market cap:
$552.24 million
Shares in issue:
68.60 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Andrew Hirsch
    President, Chief Executive Officer, Director
  • Kendra Adams
    Chief Financial Officer, Treasurer
  • Kelly Schick
    Chief People Officer
  • Mark Mossler
    Chief Accounting Officer
  • Stewart Fisher
    Chief Scientific Officer
  • Scott Boyle
    Chief Business Officer
  • Leonard Reyno
    Chief Medical Officer
  • Jolie Siegel
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.